Maximilian Christopeit
Priv.-Doz. Dr. med.
Maximilian Christopeit
  • Facharzt für Innere Medizin
  • Facharzt für Innere Medizin und Hämatologie und Onkologie
  • Infektiologie
  • 1.Arbeitsbereich
Sprachen
Deutsch (Muttersprache)
Englisch

Fachgebiete

Tätigkeitsschwerpunkte

Publikationen

Zurück
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
Vor

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
Schroeder T, Stelljes M, Christopeit M, Esseling E, Scheid C, Mikesch J, Rautenberg C, Jäger P, Cadeddu R, Drusenheimer N, Holtick U, Klein S, Trenschel R, Haas R, Germing U, Kröger N, Kobbe G
HAEMATOLOGICA. 2023;108(11):3001-3010.

Detection of human herpes virus 6 DNA and chromosomal integration after allogeneic hematopoietic stem cell transplantation: a retrospective single center analysis
Berneking L, Both A, Langebrake C, Aepfelbacher M, Lütgehetmann M, Kröger N, Christopeit M
TRANSPL INFECT DIS. 2022;24(3):e13836.

Chemotherapie bei Bronchialkarzinom
Langebrake C, Christopeit M
2022. Medikationsmanagement im Krankenhaus. Gross I, Fischer A, Knoth H (Hrsg.). 1. Aufl. Stuttgart: Deutscher Apotheker Verlag, 242-245.

Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis
Mannina D, Badbaran A, Wolschke C, Klyuchnikov E, Christopeit M, Fehse B, Kröger N
BONE MARROW TRANSPL. 2022;57(3):510-512.

Comparison of immune reconstitution between anti-T-lymphocyte globulin and post-transplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation
Massoud R, Gagelmann N, Fritzsche-Friedland U, Zeck G, Heidenreich S, Wolschke C, Ayuk F, Christopeit M, Kröger N
HAEMATOLOGICA. 2022;107(4):857-867.

Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza
Brehm T, van der Meirschen M, Hennigs A, Roedl K, Jarczak D, Wichmann D, Frings D, Nierhaus A, Oqueka T, Fiedler W, Christopeit M, Kraef C, Schultze A, Lütgehetmann M, Addo M, Schmiedel S, Kluge S, Schulze Zur Wiesch J
SCI REP-UK. 2021;11(1):.

"Per aspera ad astra".. die Facharztreife
Christopeit M, Oing C, Höffken K
ONKOLOGE. 2021;2021(27, suppl issue 1):2-4.

Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection
Christopeit M, Reichard M, Niederwieser C, Massoud R, Klyuchnikov E, Haase N, Wolschke C, Ayuk F, Heidenreich S, Kröger N
BONE MARROW TRANSPL. 2021;56(6):1478-1481.

Scabies crustosa in a recipient of an allogeneic stem cell transplantation
Christopeit M, Wichmann D
INFECTION. 2021;49(2):375-376.

A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation
Gagelmann N, Badbaran A, Beelen D, Salit R, Stölzel F, Rautenberg C, Becker H, Radujkovic A, Panagiota V, Bogdanov R, Christopeit M, Park Y, Nibourel O, Luft T, Koldehoff M, Corsten M, Heuser M, Finke J, Kobbe G, Platzbecker U, Robin M, Scott B, Kröger N
BLOOD ADV. 2021;5(6):1760-1769.

Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia
Gagelmann N, Bogdanov R, Stölzel F, Rautenberg C, Panagiota V, Becker H, Radujkovic A, Luft T, Christopeit M, Finke J, Platzbecker U, Ditschkowski M, Schroeder T, Koldehoff M, Heuser M, Kobbe G, Beelen D, Germing U, Kröger N
BIOL BLOOD MARROW TR. 2021;27(1):95.e1-95.e4.

TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Gagelmann N, Wolschke C, Klyuchnikov E, Christopeit M, Ayuk F, Kröger N
FRONT IMMUNOL. 2021;12:.

Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML
Klyuchnikov E, Christopeit M, Badbaran A, Bacher U, Fritsche-Friedland U, von Pein U, Wolschke C, Kröger N
EUR J HAEMATOL. 2021;106(5):606-615.

Infekt unter oraler Tumortherapie
Langebrake C, Christopeit M
2021. Medikationsmanagement im Krankenhaus. Gross I, Fischer A, Knoth H (Hrsg.). 1. Aufl. Stuttgart: 247-250.

Correction: Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
Modemann F, Ayuk F, Wolschke C, Christopeit M, Janson D, von Pein U, Kröger N
BONE MARROW TRANSPL. 2021;56(10):2617.

Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML
Niederwieser C, Morozova E, Zubarovskaya L, Zabelina T, Klyuchnikov E, Janson D, Wolschke C, Christopeit M, Ayuk F, Moiseev I, Afanasyev B, Kröger N
BONE MARROW TRANSPL. 2021;56(11):2834-2841.

Viral Dynamics of SARS-CoV-2 in Critically Ill Allogeneic Hematopoietic Stem Cell Transplant Recipients and Immunocompetent Patients with COVID-19
Roedl K, Heidenreich S, Pfefferle S, Jarczak D, Urbanowicz T, Nörz D, Aepfelbacher M, Kröger N, Kluge S, Lütgehetmann M, Christopeit M, Wichmann D
AM J RESP CRIT CARE. 2021;203(2):242-245.

Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19
Woo M, Haag F, Nierhaus A, Jarczak D, Roedl K, Mayer C, Brehm T, van der Meirschen M, Hennigs A, Christopeit M, Fiedler W, Karagiannis P, Burdelski C, Schultze A, Huber S, Addo M, Schmiedel S, Friese M, Kluge S, Schulze Zur Wiesch J
ISCIENCE. 2021;24(7):102752.

Incidence and Outcome of Late Relapse after Allogeneic Stem Cell Transplantation for Myelofibrosis
Atagunduz I, Christopeit M, Ayuk F, Zeck G, Wolschke C, Kröger N
BIOL BLOOD MARROW TR. 2020;26(12):2279-2284.

Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis
Atagunduz I, Klyuchnikov E, Wolschke C, Janson D, Heidenreich S, Christopeit M, Ayuk F, Kröger N
CANCERS. 2020;12(11):.

Clonal Evolution after Allogeneic Hematopoietic Stem Cell Transplantation
Christopeit M, Badbaran A, Alawi M, Flach J, Fehse B, Kröger N
BIOL BLOOD MARROW TR. 2020;26(7):e167-e170.

Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1
Eberhard J, Angin M, Passaes C, Salgado M, Monceaux V, Knops E, Kobbe G, Jensen B, Christopeit M, Kröger N, Vandekerckhove L, Badiola J, Bandera A, Raj K, van Lunzen J, Hütter G, Kuball J, Martinez-Laperche C, Balsalobre P, Kwon M, Díez-Martín J, Nijhuis M, Wensing A, Martinez-Picado J, Schulze Zur Wiesch J, Sáez-Cirión A
SCI TRANSL MED. 2020;12(542):.

Major central nervous system complications after allogeneic stem cell transplantation: a large retrospective study on 888 consecutive adult patients
Mannina D, Berneking L, Both A, Timm W, Urbanowicz T, Wolschke C, Ayuk F, Fischer N, Fiehler J, Grzyska U, Rösner S, Choe C, Kröger N, Christopeit M
EUR J HAEMATOL. 2020;105(6):722-730.

Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
Modemann F, Ayuk F, Wolschke C, Christopeit M, Janson D, von Pein U, Kröger N
BONE MARROW TRANSPL. 2020;55(12):2286-2293.

Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression
Novak P, Klyuchnikov E, von Pein U, Güllstorf M, Christopeit M, Ayuk F, Geffken M, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2020;55(9):1817-1820.

Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome
Novak P, Zabelina T, Wolschke C, Ayuk F, Christopeit M, Kröger N
BIOL BLOOD MARROW TR. 2020;26(11):2047-2052.

Monocenter study on epidemiology, outcomes, and risk factors of infections in recipients of 166 allogeneic stem cell transplantations during 1 year
Samek M, Iversen K, Belmar Campos C, Berneking L, Langebrake C, Wolschke C, Ayuk F, Kröger N, Christopeit M
EUR J HAEMATOL. 2020;105(2):126-137.

DAMIAN an open source bioinformatics tool for fast, systematic and cohort based analysis of microorganisms in diagnostic samples
Alawi M, Burkhardt L, Indenbirken D, Reumann K, Christopeit M, Kröger N, Lütgehetmann M, Aepfelbacher M, Fischer N, Grundhoff A
SCI REP-UK. 2019;9(1):16841.

Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) Are Associated with Poorer Outcome after Single Mismatch Unrelated Donor Stem Cell Transplantation: A Study of the Cooperative Transplant Study Group (KTS) of the German Group for Bone Marrow and Stem Cell Transplantation (DAG-KBT)
Ayuk F, Bornhäuser M, Stelljes M, Zabelina T, Wagner E, Schmid C, Christopeit M, Guellstorf M, Kröger N, Bethge W
TRANSFUS MED HEMOTH. 2019;46(5):370-375.

Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years
Daghia G, Zabelina T, Zeck G, von Pein U, Christopeit M, Wolschke C, Ayuk F, Kröger N
EUR J HAEMATOL. 2019;103(4):370-378.

Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation
Frick M, Chan W, Arends C, Hablesreiter R, Halik A, Heuser M, Michonneau D, Blau O, Hoyer K, Christen F, Galan-Sousa J, Noerenberg D, Wais V, Stadler M, Yoshida K, Schetelig J, Schuler E, Thol F, Clappier E, Christopeit M, Ayuk F, Bornhäuser M, Blau I, Ogawa S, Zemojtel T, Gerbitz A, Wagner E, Spriewald B, Schrezenmeier H, Kuchenbauer F, Kobbe G, Wiesneth M, Koldehoff M, Socié G, Kroeger N, Bullinger L, Thiede C, Damm F
J CLIN ONCOL. 2019;37(5):375-385.

Reduced intensity allogeneic stem cell transplantation for younger patients with myelofibrosis
Mannina D, Zabelina T, Wolschke C, Heinzelmann M, Triviai I, Christopeit M, Badbaran A, Bonmann S, von Pein U, Janson D, Ayuk F, Kröger N
BRIT J HAEMATOL. 2019;186(3):484-489.

Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation
Zeiser R, Beelen D, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, Klusmann J, Kobbe G, Lübbert M, Müller-Tidow C, Platzbecker U, Rösler W, Sauer M, Schmid C, Schroeder T, Stelljes M, Kröger N, Müller L
BIOL BLOOD MARROW TR. 2019;25(4):e128-e140.

Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Ayuk F, Beelen D, Bornhäuser M, Stelljes M, Zabelina T, Finke J, Kobbe G, Wolff D, Wagner E, Christopeit M, Schmid C, Ottinger H, Groth C, Faul C, Bertz H, Rachlis E, Wolschke C, Schetelig J, Horn P, Mytilineos J, Guellstorf M, Kelsch R, Fleischhauer K, Kröger N, Bethge W
BIOL BLOOD MARROW TR. 2018;24(12):2558-2567.

Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT
Christopeit M, Labopin M, Gorin N, Saraceni F, Passweg J, Forcade E, Maertens J, Van Lint M, Bosi A, Niederwieser D, Ehninger G, Polge E, Mohty M, Nagler A
AM J HEMATOL. 2018;93(12):1532-1542.

Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation
Kröger N, Shahnaz Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F, Wolschke C
BIOL BLOOD MARROW TR. 2018;24(10):2152-2156.

Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
Mellinghoff S, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, Hasenkamp J, Kiehl M, Koldehoff M, Krause S, Lehners N, von Lilienfeld-Toal M, Löhnert A, Maschmeyer G, Teschner D, Ullmann A, Penack O, Ruhnke M, Mayer K, Ostermann H, Wolf H, Cornely O
ANN HEMATOL. 2018;97(2):197-207.

Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO)
Ruhnke M, Behre G, Buchheidt D, Christopeit M, Hamprecht A, Heinz W, Heussel C, Horger M, Kurzai O, Karthaus M, Löffler J, Maschmeyer G, Penack O, Rieger C, Rickerts V, Ritter J, Schmidt-Hieber M, Schuelper N, Schwartz S, Ullmann A, Vehreschild J, von Lilienfeld-Toal M, Weber T, Wolf H
MYCOSES. 2018;61(11):796-813.

Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis
Shahnaz Syed Abd Kadir S, Christopeit M, Wulf G, Wagner E, Bornhauser M, Schroeder T, Crysandt M, Mayer K, Jonas J, Stelljes M, Badbaran A, Ayuketang Ayuk F, Triviai I, Wolf D, Wolschke C, Kröger N
EUR J HAEMATOL. 2018;101(3):305-317.

Acute hepatitis as a prequel to very severe aplastic anemia
Weiler-Normann C, Hartl J, Weidemann S, von Pein U, Fiedler W, Schramm C, Brinkert F, Kröger N, Christopeit M
Z GASTROENTEROL. 2018;56(1):51-54.

Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
Heinz W, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely O, Einsele H, Karthaus M, Link H, Mahlberg R, Neumann S, Ostermann H, Penack O, Ruhnke M, Sandherr M, Schiel X, Vehreschild J, Weissinger F, Maschmeyer G
ANN HEMATOL. 2017;96(11):1775-1792.

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation
Kröger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz M, Shahswar R, Ayuketang F, Gehlhaar M, Wolschke C, Bollin R, Walter C, Dugas M, Wiehlmann L, Lehmann U, Koenecke C, Chaturvedi A, Alchalby H, Stadler M, Eder M, Christopeit M, Göhring G, Koenigsmann M, Schlegelberger B, Kreipe H, Ganser A, Stocking C, Fehse B, Thol F, Heuser M
BIOL BLOOD MARROW TR. 2017;23(7):1095-1101.

ABR, a novel inducer of transcription factor C/EBPα, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia
Namasu C, Katzerke C, Bräuer-Hartmann D, Wurm A, Gerloff D, Hartmann J, Schwind S, Müller-Tidow C, Hilger N, Fricke S, Christopeit M, Niederwieser D, Behre G
ONCOTARGET. 2017;8(61):103626-103639.

Impact of molecular residual disease post allografting in myelofibrosis patients
Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuketang F, Triviai I, Zander A, Alchalby H, Bacher U, Fehse B, Kröger N
BONE MARROW TRANSPL. 2017;52(11):1526-1529.

Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation
Badbaran A, Fehse B, Christopeit M, Aranyossy T, Ayuketang F, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2016;51(6):872-3.

When is second allogeneic HSCT for relapse of acute leukaemia an option?
Christopeit M
BONE MARROW TRANSPL. 2016;51(2):184-5.

Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with MDS
Christopeit M, Badbaran A, Alawi M, Zabelina T, Zeck G, Wolschke C, Ayuketang F, Kröger N
EUR J HAEMATOL. 2016;97(3):288-96.

Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis
Christopeit M, Badbaran A, Zabelina T, Zeck G, Fehse B, Ayuketang F, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2016;51(10):1391-1393.

Suspected encephalitis with Candida tropicalis and Fusarium detected by unbiased RNA sequencing
Christopeit M, Grundhoff A, Rohde H, Belmar-Campos C, Grzyska U, Fiehler J, Wolschke C, Kröger N, Fischer N
ANN HEMATOL. 2016;95(11):1919-1921.

Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates
Klupp E, Both A, Belmar Campos C, Büttner H, König C, Christopeit M, Christner M, Aepfelbacher M, Rohde H
EUR J CLIN MICROBIOL. 2016;35(12):1957-1961.

Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis
Robin M, Porcher R, Wolschke C, Sicre de Fontbrune F, Alchalby H, Christopeit M, Cassinat B, Zabelina T, Peffault de Latour R, Ayuketang F, Socié G, Kröger N
BIOL BLOOD MARROW TR. 2016;22(7):1206-11.

CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
Schmidt-Hieber M, Silling G, Schalk E, Heinz W, Panse J, Penack O, Christopeit M, Buchheidt D, Meyding-Lamadé U, Hähnel S, Wolf H, Ruhnke M, Schwartz S, Maschmeyer G
ANN ONCOL. 2016;27(7):1207-25.

Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology
von Lilienfeld-Toal M, Berger A, Christopeit M, Hentrich M, Heussel C, Kalkreuth J, Klein M, Kochanek M, Penack O, Hauf E, Rieger C, Silling G, Vehreschild M, Weber T, Wolf H, Lehners N, Schalk E, Mayer K
EUR J CANCER. 2016;67:200-212.

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria
Ayuketang F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N
ANN HEMATOL. 2015;94(10):1727-32.

Epigenetic reprogramming and blood development
Christopeit M
EPIGENOMICS-UK. 2015;7(1):9-11.

Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation.
Mendorf A, Klyuchnikov E, Langebrake C, Rohde H, Ayuketang F, Regier M, Christopeit M, Zabelina T, Bacher A, Stübig T, Wolschke C, Bacher U, Kroger N
ACTA HAEMATOL-BASEL. 2015;134(3):146-154.

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Okoye-Okafor U, Bartholdy B, Cartier J, Gao E, Pietrak B, Rendina A, Rominger C, Quinn C, Smallwood A, Wiggall K, Reif A, Schmidt S, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari S, Antony-Debre I, Mitchell K, Wang H, Kao Y, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams N, Schwartz B, McCabe M, Maciejewski J, Verma A, Steidl U
NAT CHEM BIOL. 2015;11(11):878-86.

HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia
Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat T, Okoye-Okafor U, Todorova T, Greally J, Levine R, Melnick A, Verma A, Steidl U
J CLIN INVEST. 2014;124(3):1158-67.

Epigenetic signatures as prognostic tools in acute myeloid leukemia and myelodysplastic syndromes
Christopeit M, Bartholdy B
EPIGENOMICS-UK. 2014;6(4):371-4.

Relapse assessment following allogeneic SCT in patients with MDS and AML
Christopeit M, Kröger N, Haferlach T, Bacher U
ANN HEMATOL. 2014;93(7):1097-110.

Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology
Hentrich M, Schalk E, Schmidt-Hieber M, Chaberny I, Mousset S, Buchheidt D, Ruhnke M, Penack O, Salwender H, Wolf H, Christopeit M, Neumann S, Maschmeyer G, Karthaus M
ANN ONCOL. 2014;25(5):936-47.

Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial
Koenigsmann M, Casper J, Kahl C, Basara N, Sayer H, Behre G, Theurich S, Christopeit M, Mohren M, Reichle A, Metzner B, Ganser A, Stadler M, Uharek L, Balleisen L, Hinke A, Hinke R, Niederwieser D
BONE MARROW TRANSPL. 2014;49(3):410-5.

Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO)
Penack O, Becker C, Buchheidt D, Christopeit M, Kiehl M, von Lilienfeld-Toal M, Hentrich M, Reinwald M, Salwender H, Schalk E, Schmidt-Hieber M, Weber T, Ostermann H
ANN HEMATOL. 2014;93(7):1083-95.

Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer
Bhattacharyya S, Yu Y, Suzuki M, Campbell N, Mazdo J, Vasanthakumar A, Bhagat T, Nischal S, Christopeit M, Parekh S, Steidl U, Godley L, Maitra A, Greally J, Verma A
NUCLEIC ACIDS RES. 2013;41(16):e157.

Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML
Christopeit M, Heiland A, Binder M, Zabelina T, Ayuketang F, Horn C, Haferlach T, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(9):1257-9.

Cyclosporine area under the curve after allogeneic hematopoietic stem cell transplantation is an indicator of Epstein-Barr virus DNAemia
Christopeit M, Janssen N, Weber T, Bacher U, Lautenschläger C, Oehme A, Kekulé A, Schmoll H
LEUKEMIA LYMPHOMA. 2013;54(1):133-7.

Right flank pain and high fever in a neutropenic patient with acute lymphoblastic leukaemia
Christopeit M, Lindner A, Surov A, Weber T, Vehreschild M, Bialek R, Schmoll H
MYCOSES. 2013;56(1):90-2.

Evaluation of BM cytomorphology after allo-SCT in patients with MDS
Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E, Binder M, Ayuketang F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(3):465-6.

Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms
Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat T, Sohal D, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski J, Melnick A, Greally J, Steidl U, Moliterno A, Verma A
CANCER RES. 2013;73(3):1076-85.

Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse
Pfeiffer T, Schleuning M, Mayer J, Haude K, Tischer J, Buchholz S, Bunjes D, Bug G, Holler E, Meyer R, Greinix H, Scheid C, Christopeit M, Schnittger S, Braess J, Schlimok G, Spiekermann K, Ganser A, Kolb H, Schmid C
HAEMATOLOGICA. 2013;98(4):518-25.

Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Vehreschild M, Vehreschild J, Hübel K, Hentrich M, Schmidt-Hieber M, Christopeit M, Maschmeyer G, Schalk E, Cornely O, Neumann S
ANN ONCOL. 2013;24(5):1189-202.

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study
Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen D, Stuhler G, Stelljes M, Schwerdtfeger R, Christopeit M, Behre G, Faul C, Vogel W, Schumm M, Handgretinger R, Kanz L, Bethge W
HAEMATOLOGICA. 2012;97(10):1523-31.

Letzte Aktualisierung aus dem FIS: 26.07.2024 - 00:43 Uhr